| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | -2377.58% | — | -1116.95% | -540.87% | -184.78% | -755.86% | -159.43% | -17416.49% | -8678.23% | -7349.13% | -1865.53% |
| EBITDA Margin | — | -2368.83% | — | -1112.39% | -538.65% | -183.32% | -754.45% | -157.68% | -17348.80% | -8636.44% | -7252.60% | -1809.75% |
| Net Margin | — | -1815.34% | — | -949.65% | -324.27% | -132.51% | -471.92% | -63.62% | -5547.77% | -2579.18% | -5298.27% | -2330.60% |
| Current Ratio | 13.54 | 7.34 | 1.00 | 3.52 | 1.84 | 1.13 | 0.21 | 0.18 | 0.76 | 4.56 | 11.54 | 0.23 |
| Quick Ratio | 13.54 | 7.34 | 1.00 | 3.52 | 1.84 | 1.13 | 0.21 | 0.18 | 0.76 | 4.56 | 11.54 | 0.23 |
| Debt / Equity | — | — | — | — | -0.03 | -0.00 | -0.11 | -0.19 | — | -0.12 | — | -0.00 |
| ROE | -41.86% | -129.10% | 82.05% | 178.44% | 133.34% | 10.61% | 26.61% | 9.55% | 10.69% | 17.98% | 35.27% | 7.24% |
| ROA | -30.00% | -48.25% | -183.79% | -57.66% | -50.98% | -57.47% | -140.77% | -92.43% | -57.83% | -30.01% | -30.04% | -278.75% |
| Asset Turnover | 0.00 | 0.03 | 0.00 | 0.06 | 0.16 | 0.43 | 0.30 | 1.45 | 0.01 | 0.01 | 0.01 | 0.12 |
| Book Value / Share | — | — | — | — | — | — | — | — | — | — | — | — |
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule drug candidates to treat diabetes and other chronic diseases. Its lead product candidate, cadisegliatin (TTP399), is an orally administered, liver-selective glucokinase activator in Phase 3 clinical trials as a potential adjunctive therapy to insulin for type 1 diabetes patients. The company advances additional molecules targeting metabolic and inflammatory conditions, including TTP273, an oral glucagon-like peptide 1 receptor agonist for type 2 diabetes; HPP737, a non-central nervous system penetrant phosphodiesterase type 4 inhibitor for inflammatory diseases; and others such as HPP593, Azeliragon, and HPP3033 addressing oxidative stress-related disorders. vTv Therapeutics Inc. maintains license agreements, including with Newsoara Biopharma for phosphodiesterase type 4 inhibitors like HPP737, supporting global development efforts. Founded in 2015 and headquartered in High Point, North Carolina, the company operates in the biotechnology sector, emphasizing innovative oral treatments to address unmet needs in chronic disease management.